This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abraham, M. R. Articles by Gerstenblith, G. Search for Related Content PubMed PubMed Citation Articles by Abraham, M. R. Articles by Gerstenblith, G. Related Collections Related Article

(Circulation Research. 2007;100:447.)
© 2007 American Heart Association, Inc.

Editorials

Preconditioning Stem Cells for Cardiovascular Disease

An Important Step Forward

M. Roselle Abraham, Gary Gerstenblith

From the Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Md.

Correspondence to Gary Gerstenblith, MD, 591 Carnegie, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287. E-mail gblith@jhmi.edu

See related article, pages 545–555

Key Words: skeletal myoblast transplantation • cytoprotection • preconditioning

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The promise of stem cell therapies to regenerate new myocardium and/or to enhance intrinsic repair processes has generated enthusiasm in the scientific and clinical communities, as well as among the public and its state and national representatives. This enthusiasm is based primarily on the limited inherent cardiac regeneration capability, the increased worldwide incidence of cardiovascular disease because of the aging of the population in the developed world and adverse consequences of lifestyle changes associated with industrialization and urbanization in developing countries, the fact that left ventricular dysfunction is the final common pathway for most forms of cardiovascular disease, and the fact that despite advances in medical and device therapies, mortality, repeated hospitalization rates, and quality of life limitations in patients with left ventricular dysfunction remain at unacceptable levels.

The cell type studied most extensively in the clinical setting of chronic left ventricular dysfunction is the skeletal myoblast (SkM). Advantages of this approach include demonstrated improved cardiac performance in animal models and relatively easy accessibility to large numbers of autologous stem cells in patient populations. However, the largest and most recent placebo-controlled, randomized trial (Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial)¹ did not demonstrate sustained efficacy as defined by the primary end point, global ejection fraction, although secondary end points of changes in left ventricular volumes were significantly improved in the high-dose (800 million cells) group. Efficacy for any cell product is certainly dependent on delivery to the intended region, an issue largely addressed with direct injection protocols, and then . . . [Full Text of this Article]

Related Article:

Pharmacologically Preconditioned Skeletal Myoblasts Are Resistant to Oxidative Stress and Promote Angiomyogenesis via Release of Paracrine Factors in the Infarcted Heart

Muhammad Idris Niagara, Husnain Kh. Haider, Shujia Jiang, and Muhammad Ashraf
Circ. Res. 2007 100: 545-555. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				N. Ahmad, Y. Wang, A. K. Ali, and M. Ashraf Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H387 - H391. [Abstract] [Full Text] [PDF]